Search results
Results From The WOW.Com Content Network
San Diego Business Journal; San Diego City Beat; San Diego Jewish Journal; San Diego Magazine; San Diego Reader; San Diego Union-Tribune (acquired by Tribune Publishing) Times of San Diego; Retail. Le Travel Store (closed) Mor Furniture; Petco; PriceSmart; Sports. BikeBandit; BMC USA; Competitor Group, Inc. Ellsworth Handcrafted Bicycles ...
Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it. [3] The inhibition to the mutation has shown to shrink the size of its tumors. [4] The company is based in San Diego, California. [5] The company’s name comes from the Italian word for “targeted” (Mirati).
Arena Pharmaceuticals Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting ...
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. [14] In 1997, the company relocated all operations and management from Vermont to San Diego, California as a strategic move to garner partnerships with other biotechnology companies. [14]
Trius was founded by the last Chief Financial Officer John Schmid and Chief Scientific Officer John Finn. [16] Other executives included Chief Executive Officer Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, Chief Commercial Officer Craig Thompson, [17] and Chief Development Officer Ken Bartizal. [18]
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, [7] and Lawrence Steinman of Stanford University. [8] [9] The company was backed by Avalon Ventures among others. [8]
The Center for Innovative Phage Applications and Therapeutics (IPATH) is the first phage therapy center in North America, founded in the UC San Diego School of Medicine in June 2018, with seed funding from UC San Diego Chancellor Pradeep Khosla. [3]
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. [2]